Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May
Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Lags Revenue Estimates
Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update
Foghorn Therapeutics Inc. (FHTX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting
Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting
Contrasting Foghorn Therapeutics (NASDAQ:FHTX) and Rocket Pharmaceuticals (NASDAQ:RCKT)
Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Beats Revenue Estimates
Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Average Rating of “Buy” from Brokerages
Foghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Average Rating of “Buy” from Brokerages
Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff
Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% Premium
Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026
3 Cancer Stocks to Buy Amid Rapid Advances in Cancer Treatment
Estrella Immunopharma (NASDAQ:ESLA) & Foghorn Therapeutics (NASDAQ:FHTX) Head-To-Head Contrast
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Average Recommendation of “Buy” from Analysts
Foghorn Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
Does Foghorn Therapeutics (FHTX) Have the Potential to Rally 133.27% as Wall Street Analysts Expect?
Foghorn Therapeutics Inc. (FHTX) Reports Q3 Loss, Beats Revenue Estimates
Foghorn Therapeutics Provides Third Quarter 2025 Financial and Corporate Update
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
Foghorn Therapeutics Inc. (FHTX) Discusses Pipeline Updates for Selective ARID1B, CBP and EP300 Degrader Programs Transcript
Foghorn Therapeutics Announces Updates for Selective ARID1B, Selective CBP and Selective EP300 Degrader Programs
Foghorn Therapeutics Announces Significant Progress for Selective ARID1B Degrader at the 8th Annual TPD and Induced Proximity Summit
Wall Street Analysts Predict a 130.63% Upside in Foghorn Therapeutics (FHTX): Here's What You Should Know
IQVIA and Flagship Pioneering Announce Strategic Collaboration to Accelerate the Development of Breakthrough Life Sciences Companies
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
Foghorn Therapeutics (FHTX) Upgraded to Buy: Here's Why
Here's Why Foghorn Therapeutics (FHTX) Looks Ripe for Bottom Fishing
Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Lags Revenue Estimates
Foghorn Therapeutics Provides Second Quarter 2025 Financial and Corporate Update
Foghorn Therapeutics to Participate in Four Upcoming Investor Conferences
Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Misses Revenue Estimates
Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update
Foghorn Therapeutics to Participate in the Citizens Life Sciences Conference
Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors
Foghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline Update
Foghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual Meeting
Foghorn Therapeutics Announces New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and EP300 Degrader Programs at 2025 AACR Meeting
Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Lags Revenue Estimates
Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook
Will Foghorn Therapeutics Inc. (FHTX) Report Negative Q4 Earnings? What You Should Know
Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences
Foghorn Therapeutics (FHTX) Soars 11.4%: Is Further Upside Left in the Stock?
Foghorn Therapeutics (FHTX) Loses -23.05% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner